Heterogeneity among the primary studies included in a systematic review (SR) is one of the most challenging considerations for systematic reviewers. Current practices in anaesthesiology SRs have not been evaluated, but traditional methods may not provide sufficient information to evaluate the true nature of these differences. We address these issues by examining the practices for evaluating heterogeneity in anesthesiology reviews. Also, we propose a mapping method for presenting heterogeneous aspects of the primary studies in SRs.We evaluated heterogeneity practices reported in SRs published in highly ranked anesthesiology journals and Cochrane reviews. Elements extracted from the SRs included heterogeneity tests, models used, analyses conducted, plots used, and I 2 values. Additionally, we selected a SR to develop an evidence map in order to display clinical heterogeneity. Our statistical analysis showed 150/207 SRs reporting a test for statistical heterogeneity. Plots were used in 138 reviews to display heterogeneity. Subgroup analyses were the most commonly reported analysis (54%). Meta-regression and sensitivity analyses were used sparingly (25%; 23% respectively). A random effects model was most commonly reported (33%). Heterogeneity statistics across meta-analyses suggested that, in our sample, the majority (55%) did not present sufficient heterogeneity to be of great concern. Cochrane reviews (n¼58) were also analysed. Plots were used in 88% of Cochrane reviews. Subgroup analysis was used in 59% Cochrane reviews, while sensitivity analysis was used in 62%. Many reviews did not provide sufficient detail regarding heterogeneity. We are calling for improvement to reporting practices.
adjuncts also varied across studies. 3 These differences were noted so that readers could consider the results and determine whether primary studies were suitable for synthesis. In systematic reviews, the diversity among studies is referred to as heterogeneity. The Cochrane Collaboration delineates three types. Clinical heterogeneity refers to differences between patients, interventions, or outcomes. Methodological heterogeneity describes differences in study design and risk of bias. Statistical heterogeneity is represented by variability in the intervention effects being examined across studies and is a consequence of either clinical or methodological heterogeneity, or both. 4 Addressing heterogeneity is one of the most difficult aspects of many systematic reviews. 5 In addition, common reporting guidelines such as the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) 6 and the Meta-Analyses and Systematic
Reviews of Observational Studies (MOOSE) 7 recommend that authors describe methods of combining study results and accounting for heterogeneity appropriately. Following these guidelines is now a requirement of many journals. Current practices focus on statistical heterogeneity by reporting the outcomes of a statistical test and using the magnitude of the test statistic (or its significance level) as an indication of the degree of heterogeneity present among the included primary studies. These results form the basis for deciding next steps. While these practices are commonplace, they do not provide sufficient information to evaluate potential sources of heterogeneity or point to the clinical implications of the observed heterogeneity. 8 Identifying these sources may greatly enrich the readers and reviewers understanding of the SR and how findings may be interpreted. 9 In this study, we examine heterogeneity assessment practices among meta-analyses and systematic reviews in anesthesiology research. We focus on particular methods used to detect heterogeneity and examine the ways in which heterogeneity results inform decision-making. Second, we examine the extent of heterogeneity among the systematic reviews in our sample. Last, we present evidence mapping in the form of a case study using a recently published systematic review, to demonstrate how a more thorough evaluation of clinical and methodological heterogeneity moves beyond decisions based on statistical heterogeneity tests. This process allows for researchers to make informed decisions regarding the distinguishing clinical or methodological features of primary studies and for readers to form conclusions regarding the nature of heterogeneity of studies included in a meta-analysis.
Methods: statistical heterogeneity

Search criteria
PubMed searches were conducted on May 18 and May 26, 2015, using the following search string: (((("Anesthesiology" [Journal] OR "Anesthesia and analgesia" [Journal] ) OR "British journal of anaesthesia" [Journal] ) OR "Anaesthesia" [Journal] ) OR "Regional anesthesia and pain medicine" [Journal] 
Screening and data extraction
Covidence (covidence.org), a systematic review platform, was used initially to screen titles and abstracts. To qualify as a systematic review, studies had to summarize evidence across multiple studies and provide information on the search strategy, such as search terms, databases, or inclusion/exclusion criteria. 11 Meta-analyses were considered studies that applied a quantitative synthesis of results across multiple studies. 12 Two authors (M.V. & R.H.) independently screened all articles based on title and abstract, after which a follow up meeting was held to discuss differences in screening. Any disagreements were settled by consensus. Full-text articles were next obtained via EndNote for extracting relevant study features. The authors designed an extraction manual to ensure accuracy in extraction. Before releasing the extraction manual to individual authors, the manual was piloted based on a subset of systematic reviews. The following elements were included in the manual: a) the statistical test used to evaluate heterogeneity; b) sample size; c) a priori threshold for statistical significance; d) type of model (random, fixed, mixed, or both); e) whether reviewers selected a random effects model based on significance of the heterogeneity test; f) whether reviewers used a random effects model without explanation; g) what type of plot was used to evaluate heterogeneity, if any; h) whether the plot was published as a figure in the manuscript; i) whether follow-up analysis was conducted, and if so, the type of analysis (subgroup, meta-regression, and/or sensitivity analysis); j) what type of heterogeneity was analysed if subgroup analysis was performed (clinical or methodological); j) whether heterogeneity was mentioned in writing only; k) whether reviewers concluded there was too much heterogeneity to perform a meta-analysis; l) whether a confidence interval was reported with the heterogeneity statistic; m) whether the reviewers included an evidence map to explore clinical heterogeneity; n) whether reviewers included pre-specified subgroups; o) test of interaction, if any; p) prediction interval, if any; and q) the type of studies included in the SR (e.g. randomized trials, non-randomized trials, cohort studies).
Next, a training session was conducted to familiarize authors with the manual and extraction process. A subset of systematic reviews was used for training purposes and discussed as a group. Two authors (B.A.U. & R.H.) were next assigned three new systematic reviews for independent extraction. These data were analyzed Editor's key points
• Statistical heterogeneity describes the variation of individual study results in a meta-analysis.
• Variation can occur in either the size or direction of effect.
• Inconsistent or marked variation of effects greatly limit external validity (generalizability) of results from a systematic review.
• Strong evidence exists when consistent, reproducible results are obtained from a variety of study settings.
for inter-rater agreement by calculating Cohen's kappa. Inter-rater agreement was acceptable (k ¼ 0.80; agreement¼87 percent); therefore, each author was assigned an equal number of systematic reviews. During extraction, the following decisions were made. First, if the heterogeneity plot could be accessed within the supplementary materials, then we considered the plot as being presented in the publication. Second, if subgroup analysis or the type of model was not explicitly stated in the text but displayed on a plot (e.g. forest plot), then we counted this information. Third, general statements about predefined thresholds for P-values of statistical analyses in the meta-analysis were assumed to refer to the heterogeneity statistics as well.
Validation checks were conducted after initial extraction was completed. The validation checks allowed for each extracted element to be verified by a second author. After these checks were performed, authors (B.A.U. and R.H.) met to discuss any differences. All disagreements were settled by consensus. Third party adjudication was not necessary. Analysis of the final data was conducted using STATA 13.1.
For the second objective in this study, we used the extracted I 2 values presented in each sub-group of the systematic reviews and categorized them according the Cochrane Handbook for Systematic Reviews of Interventions: 4 • "heterogeneity might not be important" (I 2 value 0% -40%)
• "moderate heterogeneity" (I 2 value 30%-60%)
• "substantial heterogeneity" (I 2 value 50%-90%)
• "considerable heterogeneity" (I 2 value 75%-100%) I 2 is a heterogeneity statistic that expresses the percentage of the variability in effect estimates that is as a result of heterogeneity rather than sampling error 4 and allows for easier comparison of heterogeneity across reviews. Data, extraction manual, and articles were stored on Google documents and Google sheets. All data is publically available at 
Evidence mapping for clinical and methodological heterogeneity
For our case study, we used evidence mapping to generate tables, flow charts, or diagrams to factually present complicated data from multiple randomized controlled trials. 13 This process allows researchers to assess clinical and methodological heterogeneity, ideally before running any quantitative statistical heterogeneity analysis; however, it is also useful for readers to make determinations regarding the appropriateness of synthesizing a particular body of evidence. 14 Evidence maps were initially used to set research priorities but have been modified to accompany the meta-analytic process. One key feature of evidence mapping is the organization of RCTs without summarizing results.
To construct evidence maps, we modified an approach proposed by Althuis, Weed, and Frankenfield. 13 The Althuis approach focuses on observational studies and included a map to assess covariates adjusted for in multivariate analyses across the primary studies. In the present study, we included a table based on particular risk of bias components pertinent to the selected review. We took the following steps during the evidence mapping process:
1. We selected a systematic review that compared interventions and measured a specific outcome. 2. We formulated a research question based on the PICOS (population, intervention, control, outcome, study design) method.
3. We thoroughly reviewed the RCT from the selected systematic review to find a natural division to begin mapping. We examined the methods sections of each primary study in detail to understand how the RCTs were conducted. We considered all aspects of the PICOS question as we conducted our comparisons. Our goal was to categorize RCTs into two groups. We next constructed a diagram, or flow chart, to display the different groups in an easily readable format. Each study was then placed into the category to which it belonged. After the initial diagram was constructed, we examined the methods sections of the primary studies further to identify any additional groupings that could be added to the diagram. As before, each study was displayed by grouping. This concluded the construction of the first diagram. 4. We developed a second table informed by the Cochrane Risk of Bias tool and the CONSORT Guidelines. Each RCT was examined to determine if it might be susceptible to bias. The following components were evaluated: allocation concealment, blinding, eligibility of participants, and sequence generation. 5. Last, we compiled all other defining characteristics that could be extracted from the trials. These included patient population characteristics, outcome evaluation characteristics, additional interventions, and study design characteristics. This additional information was placed in the final table to display a summary of the heterogeneity mapping exercise.
Results
Article retrieval
The initial search in PubMed resulted in 315 articles. Using Covidence, we excluded 46 articles during the screening of title and abstracts. An additional eight articles were unable to be retrieved. During the full-text screening and extraction process, there were 54 articles excluded (Fig. 1 ). The final sample contained 207 systematic reviews. Table 1 outlines the types of primary studies included in systematic reviews comprising our sample. The majority were randomized controlled trials (n¼178, 85%); however, some reviews incorporated other study designs, including: NRCTs, cohorts, case controls, case series, case reports, observational studies, and cross sectional studies. The initial search for Cochrane reviews resulted in 74 articles. During the extraction process, 14 were excluded because of limited number of studies and two were withdrawn. The final sample of Cochrane studies contained 58 articles (Fig. 1 ).
Statistical heterogeneity
Of the 207 systematic reviews included in our final analysis, 150 systematic reviews reported evaluating statistical heterogeneity. Of those, 128 reported their choice of model, and 138 reported the use of a plot to display statistical heterogeneity.
Descriptive results of our analyses are presented in Table 2 . Forest plots were the most common method for visual representation of heterogeneity; however, in relatively few cases, forest plots were used in conjunction with L'abbé and Galbraith plots. Plots were consistently used across journals, yet we noticed an underrepresentation of published forest plots in regional anaesthesia and pain medicine, with only three of 12 publishing a forest plot. This result, however, should be interpreted in light of the small sample (n¼12) of systematic reviews from that journal. The majority of anaesthesia Cochrane reviews (n¼51, 88%) used forest plots as a method for visual representation of heterogeneity. Subgroup analysis (n¼156, 74%) was the most frequently reported method for assessing heterogeneity across all journals in this review, followed by sensitivity analysis (n¼48, 23%) and meta-regression (n¼34, 16%). Subgroup analysis dealt most commonly with clinical heterogeneity (n¼155).
Methodological heterogeneity was analysed using subgroup analysis in seven SRs. Subgroup analysis (n¼34, 59%) was used less frequently in Cochrane reviews, while sensitivity analysis (n¼36, 62%) was used more frequently in Cochrane reviews when compared with the published journals. Most systematic reviews did not report the model used to conduct their analyses (38%). The remaining systematic reviews used a random effects model with greater frequency (n¼69, 33%) than the fixed effects (n¼8, 4%) or mixed effects models (n¼3, 1%). Twenty-three percent (n¼48) used both fixed and random effects models. The I 2 test was the most commonly reported statistical test, both overall and across the five journals in our sample. I 2 was sometimes reported alone (11%) but most often in combination with other statistical heterogeneity tests (59%). A combination of statistical tests were reported in 121 systematic reviews. Reporting I 2 , Tau2, and X 2 jointly was the most frequently reported combination of heterogeneity tests. Sixty-seven systematic reviews (32%) did not test for statistical heterogeneity. Thirty systematic reviews did mention heterogeneity to some degree in their discussions, but did not perform a formal statistical test to evaluate it. The I 2 test was also the most commonly reported statistical test in Cochrane reviews. This metric was reported most commonly in Cochrane reviews in combination with other statistical heterogeneity tests (n¼55, 95%). Reporting I 2 , Tau2, and X 2 jointly was the most frequently reported (n¼38, 66%) combination of heterogeneity tests used in Cochrane reviews. The level of statistical significance for heterogeneity tests was reported in 58 systematic reviews. The most frequently reported P values were P<0.05 (%) and P<0.10 (%). Twenty-two systematic reviews indicated a high degree of heterogeneity from their analysis and did not conduct a meta-analysis as a result of the excessive heterogeneity between primary studies. In 39 systematic reviews, we were unable to determine whether formal heterogeneity testing led to decisions about conducting a meta-analysis. Two systematic reviews discussed prespecified subgroups for analysis. There were not instances of systematic reviewers providing confidence intervals for heterogeneity statistics or using evidence mapping.
We next summarized I 2 values reported in both subgroup and overall analyses to determine the extent of heterogeneity most often reported in anaesthesia systematic reviews (Supplementary Table S1 ). Of the 149 SRs reported statistical heterogeneity within their study, 23 SRs were excluded from this particular analysis as these reviews did not report an I 2 stat- Reviewers' comments were included in Supplementary Table S1 to indicate their decision making in light of heterogeneity issues.
Evidence mapping
To illustrate evidence mapping (see Table 3 ), we selected a systematic review by Kumar. 33 This study compared i.v. propofol with both inhalation sevoflurane and desflurane and comprised 18 clinical trials. The aim of the study was to assess whether maintenance of anaesthesia with total i.v. propofol or sevoflurane/desflurane (inhalation agents) produced better outcomes in terms of hospital admissions and postoperative pain, nausea, and vomiting. 33 Evidence mapping: Flow chart
The first step of evidence mapping is displayed in Fig. 2 . The natural division among the 18 randomized controlled trials was based on type of intervention. Propofol vs desflurane was examined in eight trials and propofol vs sevoflurane in 10 trials. After further examination of all trials, we further delineated whether each trial had used nitrous oxide. The propofol vs sevoflurane trials that used nitrous oxide were more evenly distributed than trials that examined propofol vs desflurane, where the majority used nitrous oxide. This initial flow chart separating the randomized controlled trials based on interventional aspects serves as the basis for the final evidence map shown in Table 4 . This flow chart constitutes the groupings in Table 4 and is labelled at the top of the chart.
Evidence mapping: consort guidelines table   Table 3 summarizes elements of methodological quality of the primary studies to understand patterns contributing to methodological heterogeneity. RCTs have been displayed in the categories from the initial step in the evidence mapping exercise. Participant eligibility and blinding of the patient were common features across all included trials; however, blinding of the assessor was either not performed or not reported in any of the trials. Blinding of the anaesthetist occurred only once. Sequence generation and allocation concealment were performed in less than one-third of all trials included in the meta-analysis.
Evidence mapping: overview of primary studies Table 4 is the final product of the evidence mapping exercise and displays the relevant clinical heterogeneity aspects of all trials. Table 4 includes the information from Fig. 2 along with other relevant groupings. Differences among groups of trials were noted by study location, type of surgery, induction of antiemetic medication, and mechanism of evaluating primary and 30 Unknown No Unknown Tan et al. 31 No White et al. 32 Unknown No secondary outcomes. Six different types of surgeries were reported across trials. Three different mechanisms for pain measurement and five different mechanisms for measuring nausea and vomiting were used in the primary research. Some trials did not have a mechanism for measuring pain or nausea. Five of the 18 RCTs were conducted after the yr 2000. Gynaecological surgeries were most commonly reported, all of which comprised females.
The role of evidence mapping in planning subsequent analyses
Based on the results of the mapping exercise, it would be feasible to plan for subgroup analyses a priori to evaluate potential sources of clinical or methodological heterogeneity. In the Kumar systematic review, certain clinical features identified during mapping may contribute to heterogeneity in postoperative nausea and vomiting. For example, certain types of surgery, such as breast or intra-abdominal surgery, have increased risks for postoperative nausea and vomiting. 34 Similarly, studies in which an anti-emetic was used may yield lower rates of postoperative nausea and vomiting than studies in which no anti-emetic was used. 35 Other relevant clinical factors, such as whether patients were smokers, may also be meaningful analyses to investigate the heterogeneity of study results, as smoking has a protective effect against postoperative nausea and vomiting. 36 In the Kumar review, however, the information provided from evidence mapping suggests that there are too few studies to justify these subgroup analyses, as the Cochrane Handbook suggests at least 10 studies in a metaanalysis should be available for each characteristic modeled. Hence, evidence mapping may provide a mechanism to plan for clinically (or methodologically) relevant subsequent analyses and to determine the feasibility of such analyses. 
Discussion
Widely adopted systematic review reporting guidelines, such as PRISMA 6 and MOOSE, 7 recommend that authors describe methods of combining study results and account for heterogeneity appropriately. We found that systematic reviewers handled statistical heterogeneity in a variety of different ways, while others did not address statistical heterogeneity at all. We noted some inconsistencies between our results and previous research examining heterogeneity. Huang and colleagues 37 assessed heterogeneity in 38 meta-analyses of Helicobacter pylori. Only 50% of the meta-analyses reported a statistical test for heterogeneity. In contrast, we found that only 150 (72%) systematic reviews from anaesthesiology reported a statistical test for heterogeneity. Differences were also found regarding graphical displays of heterogeneity. Espitalier and colleagues 38 reported the most common plot or graph was the L'abbé plot (57%), whereas we found six studies which used the L'abbé plot. All studies in our analysis displayed statistical heterogeneity using a forest plot (n¼138). Huang and colleagues 37 also reported forest plots as the most common graphical representation of heterogeneity. Of the methods used to examine sources of heterogeneity, subgroup analyses were reported in 54% of our systematic reviews. Espitalier and colleagues 38 reported that 90% of their metaanalyses included a subgroup analysis. However, this should be examined in light of the fact that all systematic reviews in the Espitalier and colleagues 38 study conducted a test for statistical heterogeneity. Statistical tests were also assessed for frequency of use. The I 2 statistical test (69%) was the most commonly used statistic both alone and in conjunction with other tests. In contrast, Espitalier and colleagues 38 found that I 2 was only reported in 21% of systematic reviews, equal to Cochrane's Q. Only 4% (n¼8) of systematic reviews in our sample used a fixed effects model while 33% (n¼69) used a random effects model. Interestingly, Espitalier and colleagues 38 reported that 20% of SRs used a random-effects model and 59% used a fixed effects model. Huang and colleagues 37 found that 61% of studies did not describe the model used during analysis, which is consistent with our findings (n¼79, 38%). From our review, we found that vital elements of the heterogeneity process were underreported; for example, many authors did not report on the model used for analysis. As model choice affects the calculation of the effect sizes and confidence intervals, this essential information should always be reported. Additionally, the Institute of Medicine's Standards for Systematic Reviews states that, "although the committee does not believe that any single statistical technique should be a methodological standard, it is essential that the SR [systematic review] team clearly explain and justify the reasons why it chose the technique actually used." 39 In our analysis, we found little, if any, justification for the choice of technique and recommend that such decisions be clearly explained. These decisions regarding model choice should be made a priori, and the rationale for the choice should be included in the systematic review protocol and the published report. Decisions for model selection should not be based solely on the results of a heterogeneity statistical test alone. We also found little evidence of systematic reviewers prespecifying subgroups for analysis. The Cochrane Handbook recommends the careful selection of subgroups for analysis a priori to limit the likelihood of spurious results and avoid knowledge of meta-analytic results forming the basis for subgroup selection. 4 The Handbook also suggests that these subgroups, ideally, should be derived from biological or clinical hypotheses and supported from evidence outside of the included studies. 4 Furthermore, effect modifiers should be planned for in subgroup analysis. Prognostic factors should only be used if they are thought to modify the intervention effect.
4 Another recent recommendation for reporting heterogeneity for meta-analyses is to include prediction intervals. A 95% prediction interval, by definition, estimates where the true effects are to be expected for 95% of similar studies that might be performed in the future. Prediction intervals are useful to evaluate the variability of an intervention's effect across settings and the range of possible effects in relation to harm and clinical benefit thresholds. 8 Incorporating prediction intervals with standard heterogeneity statistics would provide better information for clinical decision making as the interval estimates what effect is to be expected in future patients. It is important, however, to recognize the limitations of prediction intervals. 8 The calculations for prediction intervals assume normality, which may be difficult to achieve. Prediction intervals will be imprecise when estimates of the summary effect and between study heterogeneity are imprecise. Finally, prediction intervals are not routine outputs of metaanalytic software making their calculations more difficult. In addition to determining how heterogeneity was handled in anaesthesiology systematic reviews, we also classified the severity of heterogeneity from our sample. Across meta-analyses, we found evidence of low heterogeneity in 55% of them. The remaining meta-analyses contained moderate to high heterogeneity that warranted further scrutiny. Among these systematic reviews, 98 systematic reviewers commented on heterogeneity in the SR. Some others offered explanations for the heterogeneity: "Clinical heterogeneity between studies of GDT cannot be ignored, in relation to type of surgery, patient's characteristics, therapeutic goals, methods for achieving these goals, and monitoring." 40 Other authors cautioned readers to consider their findings in light of this evidence: "Furthermore, the latter findings were influenced by significant heterogeneity and should be therefore interpreted with caution." 41 Some reviews provided study characteristics tables;
however, the information provided in these tables did not often allow readers to determine potential sources of heterogeneity that might modify summary effects. Very rarely did systematic review authors provide a rationale in the narrative for subgroup analyses or their possible contributions to effect modification. After completing our review of anaesthesiology systematic reviews, we encourage readers and researchers to consider the considerable heterogeneity found in this field of research. Additionally, we encourage all systematic reviewers to express the level of heterogeneity present in their SR. To help bridge the gap between mentioning the statistical result of increasing heterogeneity amongst primary research being added to systematic reviews, we also strongly suggest the use of evidence mapping in order to assist in visually representing primary research differences before completing statistical tests. This will allow for transparency between researchers, physicians, and readers in order to understand the differences in primary research and how heterogeneity could possible effect clinical decision-making.
Finally, we presented a case study to make the case for evidence mapping as a mechanism for evaluating both the clinical and methodological heterogeneity across studies. The Centre for Reviews and Dissemination states that both quantitative and narrative syntheses should be accompanied by descriptive summaries of the primary studies. 42 Such summaries have been limited to basic details such as type of intervention, number of participants, patient characteristics, and outcomes. Evidence mapping is not limited to the basic details and is a more thorough process to examine diversity among primary research. Furthermore, Evidence mapping is a flexible, adaptive approach that may vary by the type and nature of the primary studies included for review. Although we constructed our evidence maps based on previously completed meta-analyses, ideally, evidence maps should be used before conducting summary effects of the primary studies, allowing reviewers to better understand the true nature of the individual studies and assist them in deciding whether a meta-analysis should be conducted. Our study has the following limitations. Only one database, Medline via PubMed, was searched to identify systematic reviews published in anaesthesiology journals. While all journals in our sample are PubMed-indexed, there is potential that our search did not retrieve all systematic reviews published during the study period. Similarly, we limited our Cochrane review search to those published by a single review group. It is possible that other review groups also published reviews on anaesthesia-related topics. In both cases, results should be interpreted in light of these limitations.
In summary, heterogeneity plays an important role in systematic review decision-making, and is one of the most difficult aspects to resolve. From our review, many authors failed to provide basic information regarding the ways in which heterogeneity was assessed, or how excessive heterogeneity was handled. Reporting practices should continue to be improved, and authors should consult PRISMA Guidelines 6 during the review process.
Future research should examine the heterogeneity practices in other areas of clinical medicine to see if results from this study are consistent with systematic reviews in other clinical specialties. Additional research should look at adherence to PRISMA Guidelines, 6 particularly with respect to the high-yield areas that have the greatest influence of summary effects.
